Strides Pharma Science Limited (BOM:532531)
650.40
+8.35 (1.30%)
At close: Apr 22, 2025
Strides Pharma Science Revenue
Strides Pharma Science had revenue of 11.54B INR in the quarter ending December 31, 2024, with 11.18% growth. This brings the company's revenue in the last twelve months to 45.79B, up 15.83% year-over-year. In the fiscal year ending March 31, 2024, Strides Pharma Science had annual revenue of 40.51B with 9.83% growth.
Revenue (ttm)
45.79B
Revenue Growth
+15.83%
P/S Ratio
1.37
Revenue / Employee
14.94M
Employees
3,065
Market Cap
62.77B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 40.51B | 3.63B | 9.83% |
Mar 31, 2023 | 36.88B | 6.18B | 20.13% |
Mar 31, 2022 | 30.70B | -2.46B | -7.41% |
Mar 31, 2021 | 33.16B | 5.64B | 20.49% |
Mar 31, 2020 | 27.52B | 5.74B | 26.33% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries | 9,398.38B |
HDFC Bank | 2,728.47B |
Tata Consultancy Services | 2,553.24B |
Bharti Airtel | 1,627.08B |
ICICI Bank | 2,006.54B |
State Bank of India | 3,409.52B |
Infosys | 1,647.16B |
Bajaj Finance | 358.05B |
Strides Pharma Science News
- 13 days ago - Strides Pharma incorporates new subsidiary ‘Pivot Path’ to boost life sciences and digital innovation - Business Upturn
- 3 months ago - Strides Pharma shares surge 5% as revenue jumps 15% YoY in Q3 FY25 - Business Upturn
- 3 months ago - Strides Pharma Q3 FY25 Results: Revenue up 15% YoY to Rs 1,154 crore, Net Profit up 60% YoY - Business Upturn
- 3 months ago - Strides Pharma receives USFDA approval for acetaminophen and ibuprofen tablets, expanding OTC portfolio - Business Upturn